| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22028 |
| Drug |
Vosoritide |
| Brand |
Voxzogo® |
| Indication |
For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed. |
| Rapid review commissioned |
09/05/2022 |
| Rapid review completed |
01/06/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vosoritide compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
| Pre-submission consultation with Applicant |
26/09/2022 |
| Full submission received from Applicant |
21/03/2023 |
| Preliminary review sent to Applicant |
24/07/2023 |
| NCPE assessment re-commenced |
22/08/2023 |
| Factual accuracy sent to Applicant |
13/09/2023 |
| NCPE assessment re-commenced |
22/09/2023 |
